DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 84 filers reported holding DYNE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $44,363,675 | -20.4% | 4,951,303 | 0.0% | 23.76% | -13.0% |
| Q2 2023 | $55,702,159 | -2.3% | 4,951,303 | 0.0% | 27.32% | +14.9% |
| Q1 2023 | $57,039,011 | -0.6% | 4,951,303 | 0.0% | 23.77% | -1.0% |
| Q4 2022 | $57,385,602 | -8.7% | 4,951,303 | 0.0% | 24.01% | +0.3% |
| Q3 2022 | $62,882,000 | +84.9% | 4,951,303 | 0.0% | 23.95% | +66.9% |
| Q2 2022 | $34,015,000 | -28.7% | 4,951,303 | 0.0% | 14.35% | -12.0% |
| Q1 2022 | $47,731,000 | -18.9% | 4,951,303 | 0.0% | 16.31% | +28.2% |
| Q4 2021 | $58,871,000 | -26.8% | 4,951,303 | 0.0% | 12.72% | -31.7% |
| Q3 2021 | $80,409,000 | -22.8% | 4,951,303 | 0.0% | 18.64% | -3.8% |
| Q2 2021 | $104,175,000 | +35.5% | 4,951,303 | 0.0% | 19.37% | +30.4% |
| Q1 2021 | $76,894,000 | -26.0% | 4,951,303 | 0.0% | 14.86% | +1.0% |
| Q4 2020 | $103,977,000 | +4.0% | 4,951,303 | 0.0% | 14.71% | -21.1% |
| Q3 2020 | $99,967,000 | – | 4,951,303 | – | 18.64% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,960,046 | $20,335,000 | 17.18% |
| MPM ASSET MANAGEMENT LLC | 4,951,303 | $34,015,000 | 14.35% |
| Atlas Venture Life Science Advisors, LLC | 8,934,902 | $61,383,000 | 10.26% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,865 | $562,568,000 | 5.87% |
| Logos Global Management LP | 2,900,000 | $19,923,000 | 3.66% |
| Deep Track Capital, LP | 3,500,000 | $24,045,000 | 1.58% |
| HighVista Strategies LLC | 241,867 | $1,662,000 | 1.00% |
| Monashee Investment Management LLC | 319,536 | $2,195,000 | 0.80% |
| RA Capital Management | 2,805,045 | $19,271,000 | 0.51% |
| Vivo Capital, LLC | 577,642 | $3,968,000 | 0.40% |